股本结构
单位：万股
| 公告日期 | 2026-10-14 | 2026-10-14 | 2026-09-24 | 2026-09-24 | 2026-09-11 | 2026-08-27 |
|---|---|---|---|---|---|---|
| 证券总股本 | 236.82 | 236.82 | 101.80 | 84.86 | 79.84 | 79.81 |
| 普通股本 | 236.82 | 236.82 | 101.80 | 84.86 | 79.84 | 79.81 |
| 优先股 | 4.63 | 未披露 | 4.63 | 4.63 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-10-13 | 2026-10-05 | 2026-09-25 | 2026-09-23 | 2026-09-11 | 2026-08-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-10-14 | 236.82 | 4.63 | 定期报告 | 2026-10-13 |
| 2026-10-14 | 236.82 | 未披露 | 定期报告 | 2026-10-05 |
| 2026-09-24 | 101.80 | 4.63 |
更多>>
Common stock offered 169,388 shares by the company
|
2026-09-25 |
| 2026-09-24 | 84.86 | 4.63 | 定期报告 | 2026-09-23 |
| 2026-09-11 | 79.84 | 未披露 | 定期报告 | 2026-09-11 |
| 2026-08-27 | 79.81 | 未披露 |
更多>>
a 1-for-15 reverse stock split of its issued and outstanding common stock
|
2026-08-31 |
| 2026-08-27 | 1197.22 | 未披露 | 定期报告 | 2026-08-27 |
| 2026-08-10 | 1057.88 | 未披露 | 定期报告 | 2026-08-05 |
| 2026-07-17 | 771.91 | 未披露 | 定期报告 | 2026-07-17 |
| 2026-05-14 | 625.93 | 未披露 | 定期报告 | 2026-05-14 |
| 2026-05-14 | 252.43 | 未披露 |
更多>>
From December 31,2025 to March 31, 2026
Issuance of common stock upon exercise of pre-funded warrants
Issuance of common stock upon completion of ELOC financing, net of offering expenses
|
2026-03-31 |
| 2026-03-30 | 194.43 | 未披露 | 定期报告 | 2026-03-30 |
| 2026-02-09 | 101.13 | 未披露 | 定期报告 | 2026-01-28 |
| 2025-10-08 | 91.07 | 未披露 | 定期报告 | 2025-10-08 |
| 2025-08-14 | 89.94 | 未披露 |
更多>>
From March 31, 2025 to June 30, 2025
Issuance of common stock upon the completion of public offerings, net of offering expenses
Stock split adjustment
|
2025-06-30 |
| 2025-06-16 | 56.75 | 未披露 |
更多>>
a 1-for-60 reverse stock split of its issued and outstanding common stock
|
2025-06-16 |
| 2025-06-12 | 3254.13 | 未披露 | 定期报告 | 2025-06-12 |
| 2025-05-14 | 2864.28 | 未披露 | 定期报告 | 2025-05-14 |
| 2025-05-14 | 2558.59 | 未披露 |
更多>>
From January 1, 2025 to March 31, 2025
Issuance of common stock upon completion of public offering, net of offering expenses
Cashless exercise of warrants into common stock
Stock split adjustment
|
2025-03-31 |
| 2025-03-13 | 1316.24 | 未披露 |
更多>>
On March 11, 2025, the Company received exchange notices from the Note Investor and the Holders with respect to an aggregate of 2,835,905 Series B Warrants, requiring the delivery of 2,749,817 shares of Common Stock.
|
2025-03-11 |
| 2025-02-05 | 1041.26 | 未披露 |
更多>>
Common Stock offered 2,638,042 shares of Common by the company.
|
2025-02-05 |
| 2025-01-30 | 777.46 | 未披露 |
更多>>
a 1-for-20 reverse stock split of its issued and outstanding common stock
|
2025-02-04 |
| 2025-01-30 | 15549.15 | 未披露 | 定期报告 | 2025-01-30 |
| 2024-12-17 | 1605.22 | 未披露 | 定期报告 | 2024-12-16 |
| 2024-12-06 | 1449.50 | 未披露 | 定期报告 | 2024-12-04 |
| 2024-11-14 | 820.94 | 未披露 |
更多>>
Glucotrack, Inc.announced the closing of 2,437,340 shares of common stock.
|
2024-11-14 |
| 2024-11-08 | 577.20 | 未披露 | 定期报告 | 2024-11-08 |
| 2024-12-17 | 547.84 | 未披露 | 定期报告 | 2024-10-03 |
| 2024-11-14 | 577.20 | 未披露 |
更多>>
From July 1, 2024 to September 30, 2024
Issuance of shares and warrants as settlement of financial liabilities
|
2024-09-30 |
| 2024-08-13 | 547.84 | 未披露 |
更多>>
From April 1, 2024 to June 30, 2024
Issuance of Common Stock upon private placement transaction
Issuance of restricted shares as compensation towards directors
|
2024-06-30 |
| 2024-05-15 | 547.86 | 未披露 |
更多>>
Every five shares of Glucotrack’s issued and outstanding Common Stock has been combined into one share of Common Stock.
|
2024-05-20 |
| 2024-05-15 | 2739.30 | 未披露 | 定期报告 | 2024-05-15 |
| 2024-05-15 | 2739.30 | 未披露 | 定期报告 | 2024-05-14 |
| 2024-03-28 | 2675.64 | 未披露 | 定期报告 | 2024-03-04 |
| 2024-04-01 | 3270.35 | 未披露 | 定期报告 | 2024-02-26 |
| 2023-05-12 | 2089.22 | 未披露 | 定期报告 | 2023-05-12 |
| 2023-04-17 | 2088.01 | 未披露 |
更多>>
Common stock offered 5,376,472 shares by the company
|
2023-04-17 |
| 2023-03-02 | 1550.36 | 未披露 | 定期报告 | 2023-02-17 |
| 2023-03-31 | 1550.07 | 未披露 |
更多>>
From January 1, 2022 to December 31, 2022
Issuance of restricted shares as compensation towards directors
Stock-based compensation
|
2022-12-31 |
| 2022-11-14 | 1547.67 | 未披露 |
更多>>
From July 1, 2022 to September 30, 2022
Issuance of restricted shares as compensation towards directors
|
2022-09-30 |
| 2022-08-15 | 1547.33 | 未披露 |
更多>>
From April 1, 2022 to June 30, 2022
Issuance of restricted shares as compensation towards directors
Stock-based compensation
|
2022-06-30 |
| 2022-05-16 | 1546.18 | 未披露 | 定期报告 | 2022-05-13 |
| 2022-05-16 | 1545.23 | 未披露 | 定期报告 | 2022-03-31 |
| 2022-03-31 | 1545.51 | 未披露 | 定期报告 | 2022-03-30 |
| 2022-03-31 | 1545.23 | 未披露 |
更多>>
From January 1, 2021 to December 31, 2021
Issuance of restricted shares as compensation to directors
|
2021-12-31 |
| 2021-11-15 | 1544.75 | 未披露 | 定期报告 | 2021-12-10 |
Common stock offered 169,388 shares by the company
a 1-for-15 reverse stock split of its issued and outstanding common stock
From December 31,2025 to March 31, 2026
Issuance of common stock upon exercise of pre-funded warrants
Issuance of common stock upon completion of ELOC financing, net of offering expenses
From March 31, 2025 to June 30, 2025
Issuance of common stock upon the completion of public offerings, net of offering expenses
Stock split adjustment
a 1-for-60 reverse stock split of its issued and outstanding common stock
From January 1, 2025 to March 31, 2025
Issuance of common stock upon completion of public offering, net of offering expenses
Cashless exercise of warrants into common stock
Stock split adjustment
On March 11, 2025, the Company received exchange notices from the Note Investor and the Holders with respect to an aggregate of 2,835,905 Series B Warrants, requiring the delivery of 2,749,817 shares of Common Stock.
Common Stock offered 2,638,042 shares of Common by the company.
a 1-for-20 reverse stock split of its issued and outstanding common stock
Glucotrack, Inc.announced the closing of 2,437,340 shares of common stock.
From July 1, 2024 to September 30, 2024
Issuance of shares and warrants as settlement of financial liabilities
From April 1, 2024 to June 30, 2024
Issuance of Common Stock upon private placement transaction
Issuance of restricted shares as compensation towards directors
Every five shares of Glucotrack’s issued and outstanding Common Stock has been combined into one share of Common Stock.
Common stock offered 5,376,472 shares by the company
From January 1, 2022 to December 31, 2022
Issuance of restricted shares as compensation towards directors
Stock-based compensation
From July 1, 2022 to September 30, 2022
Issuance of restricted shares as compensation towards directors
From April 1, 2022 to June 30, 2022
Issuance of restricted shares as compensation towards directors
Stock-based compensation
From January 1, 2021 to December 31, 2021
Issuance of restricted shares as compensation to directors